Amylyx Pharmaceuticals (AMLX) drew fresh attention after announcing that the last participant in its pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia has been randomized and dosed, marking full enrollment.
See our latest analysis for Amylyx Pharmaceuticals.
With the shares recently at $13.55, Amylyx has a 1-day share price return of 0.59%, a 30-day share price decline of 10.68%, and a 1-year total shareholder return of 282.77%. The 3-year total shareholder return remains 52.64% lower, which highlights strong recent momentum after earlier weakness.
If this kind of clinical milestone has your attention, it could be a useful moment to broaden your watchlist with 33 healthcare AI stocks
With Amylyx valued at about US$1.5b and the share price sitting well below the average analyst target and intrinsic estimates, you have to ask: is the market overlooking potential here, or already pricing in future growth?
Most Popular Narrative: 39% Undervalued
With Amylyx last closing at $13.55 against a narrative fair value of $22.20, the current price sits well below what this widely followed view implies.
The company is targeting post bariatric hypoglycemia, a condition with no FDA approved therapies and an estimated 160,000 patients in the U.S., which creates room for a first approved product like avexitide to establish a new revenue line if pricing and access are secured.
Want to see what kind of future revenue ramp this assumes, and how margins and valuation multiples are stitched together behind that target? The full narrative lays out the growth curve, the profitability bridge, and the pricing power assumptions that need to hold for $22.20 to make sense.
Result: Fair Value of $22.20 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story only holds if avexitide delivers in the single pivotal LUCIDITY trial and if payer coverage and patient uptake in post bariatric hypoglycemia match current expectations.
Find out about the key risks to this Amylyx Pharmaceuticals narrative.
Next Steps
With sentiment clearly mixed, this is the point to look at the key data yourself, weigh both sides, and move quickly to form a clear view using 1 key reward and 4 important warning signs
Looking for more investment ideas?
If Amylyx has sharpened your focus, now is the time to widen your field of vision and line up a few more candidates on your radar.
- Zero in on quality at a discount by reviewing companies that screen as potentially attractively priced with 62 high quality undervalued stocks.
- Strengthen your income stream by checking out businesses offering robust payouts with 12 dividend fortresses.
- Sleep easier at night by scanning for companies that score well on resilience using 64 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com